This document summarizes the work of Biofab, a company that aims to reduce organ transplant waiting lists by developing bio-generated organs using 3D bioprinting and stem cell technology. Biofab was founded by Cesar Loo and plans to develop organ bioprinting models using stem cells from umbilical cords, teeth, and adipose tissue. Their strategy is to establish operations in Europe and sell bioprinters, biomaterials, and stem cells to eventually bioprint tracheas, esophagi, and bladders for human transplant.